Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension


1 Arterial Investigation Unit, Medicine 4, Santa Marta’s Hospital, CHLC, Lisbon, Portugal

2 HaaPACS GmbH, Schriesheim, Germany

3 Catalyst Health Economics Consultants, Northwood, UK

4 Faculty of Life Sciences and Medicine, King’s College, London, UK

5 Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

6 Health Economics Outcomes Research Department, Daiichi-Sankyo Europe, Munich, Germany

For all author emails, please log on.